LCTX

Insider Trades

Name	Value	Action	Price	Current Price
Culley Brian MDirector, Officer: President And CEO $24k15k shares BuyMar 12, 2026 $1.63 --
Howe Jill AnnChief Financial Officer $8.8k15k shares BuyNov 26, 2024 $0.59 --
Samuel George A. IIIGeneral Counsel $9.0k15k shares BuyNov 26, 2024 $0.60 --
Mulroy Michael H.Director $23k40k shares BuyNov 22, 2024 $0.566 --
Culley Brian MDirector, Officer: President And CEO $24k40k shares BuyNov 21, 2024 $0.60 --
Howe Jill AnnChief Financial Officer $9.3k10.5k shares BuyAug 16, 2024 $0.89 --

News

marketbeat.comLineage Cell Therapeutics Q1 Earnings Call Highlightsmarketbeat.comMay 15

seekingalpha.comLineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 12

zacks.comLineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 12

businesswire.comLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatebusinesswire.comMay 12

businesswire.comLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026businesswire.comMay 5

Trade LCTX

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (LCTX) operates as a biotechnology firm in the clinical trial phase, dedicated to pioneering innovative cell-based treatments for various degenerative conditions across the United States and globally. The company's pipeline features several key therapeutic candidates: OpRegen, a replacement therapy utilizing retinal pigment epithelium cells, is currently undergoing Phase I/IIa clinical trials to address dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, is being evaluated in Phase I/IIa multicenter clinical studies for individuals suffering from acute spinal cord injuries. VAC2, an allogeneic cancer immunotherapy employing antigen-presenting dendritic cells, has advanced to Phase I clinical trials for the treatment of non-small cell lung cancer. Beyond its development pipeline, Lineage Cell Therapeutics also markets Renevia, a product designed for facial aesthetics. The company's research and development endeavors extend to exploring therapeutic solutions for a broader range of retinal and neurological disorders, as well as additional oncology indications. A strategic alliance exists between Lineage Cell Therapeutics, Inc. and Orbit Biomedical, Ltd. The organization, which was established in 1990 and is headquartered in Carlsbad, California, previously operated under the name BioTime, Inc. before rebranding in August 2019.

CEO: Brian Culley
IPO Date: Mar 5, 1992

Market Data

Open: $1.26
High: $1.29
Low: $1.21
Volume: 850.3K
Avg Volume: 1.2M
52W High: $2.09
52W Low: $0.85

Valuation

Market Cap: $302M
Enterprise Value: $268M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-19M
Revenue: $15M
Net Income: $-64M
Cash: $41M
Debt: $2.4M

Events

EarningsAug 11

EPS est. -0.03